Sigyn Therapeutics Appoints Dr. Christoph Zaba to Scientific Advisory Board to Advance Cardiovascular Disease Treatment
TL;DR
Sigyn Therapeutics gains competitive edge by appointing Dr. Christoph Zaba to its advisory board, leveraging his expertise to advance cardiovascular disease treatments.
Sigyn Therapy uses whole blood adsorption on dialysis machines to reduce Lp(a) and LDL-C levels, potentially cutting cardiovascular events by 55-98%.
Sigyn's technology expands access to life-saving cardiovascular treatments from 60 specialized centers to 7,500 dialysis clinics, improving global health outcomes.
Sigyn Therapeutics combines dialysis and apheresis to simultaneously target cholesterol and inflammation, pioneering a novel approach to combat heart disease.
Found this article helpful?
Share it with your network and spread the knowledge!
Sigyn Therapeutics, Inc. has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive experience in medical technology and extracorporeal therapies to the company. Dr. Zaba previously directed global product management in therapeutic apheresis at Fresenius Medical Care, advancing treatments in nephrology, dermatology, neurology, and cardiovascular medicine. His work included immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for removing pathogenic lipoproteins from the blood.
Lipoprotein apheresis is an extracorporeal treatment that reduces lipoprotein(a) and low-density lipoprotein cholesterol in the bloodstream. Studies have reported 55% to 98% reductions in major adverse cardiovascular events through this methodology, addressing cardiovascular disease as the leading cause of global deaths. Sigyn Therapy™ is a whole blood adsorption technology designed to reduce both Lp(a) and LDL-C while targeting inflammatory molecules that fuel cardiovascular disease progression.
The company recently disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease subjects with end-stage renal disease. Successful completion could lead to a pivotal efficacy study necessary for potential market clearance. Unlike lipoprotein apheresis, which is limited to fewer than 60 specialized centers in the U.S., Sigyn Therapy™ is designed for use on dialysis machines already located in approximately 7,500 U.S. dialysis clinics, potentially expanding treatment access significantly.
For more information on Dr. Zaba's background, visit https://www.sigyntherapeutics.com/about/scientific-advisory-board. Sigyn Therapeutics is also developing dialysis-like cancer therapies, including ImmunePrep™ to optimize immunotherapeutic antibody delivery, ChemoPrep™ to enhance targeted chemotherapy delivery, and ChemoPure™ to reduce chemotherapy toxicity. These candidates are planned for advancement through joint venture development relationships.
Curated from NewMediaWire
